Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc is positioned positively in the biopharmaceutical sector, particularly with its lead program, ficerafusp alfa, demonstrating a significantly higher objective response rate (ORR) compared to established therapies such as Keytruda, highlighting its potential efficacy in treating solid tumors. The treatment also shows promising metrics with a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, which surpass traditional benchmarks observed in similar patient populations. These advancements suggest a robust therapeutic profile that could drive future growth and valuation for the company as clinical results progress.

Bears say

Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates of a $0.51 loss, indicating a lack of operational improvement. The company faces several risks, including potential negative clinical outcomes with its lead therapy, ficerafusp alfa, and the possibility of delays in moving into registrational trials, which could hinder its development timeline. Furthermore, projected full-year losses for 2025 are anticipated at $2.27 per share, slightly better than previous estimates, yet still reflecting ongoing financial challenges and uncertainties in achieving regulatory approvals and overcoming competitive pressures.

BCAX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 5 analysts, BCAX has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.